Despite promising results in an animal model,316 a recent phase IIb clinical trial failed to demonstrate efficacy in human NASH.317 Similarly, elafibranor, a medication targeting PPARα and PPARδ, has shown some benefit in a phase IIb study;318 however, a phase 3 trial in NASH has not shown benefit in an interim analysis, leading to study discontinuation. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.